Literature DB >> 7610765

Uptake of systemically administered human anticerebellar antibody by rat Purkinje cells following blood-brain barrier disruption.

J E Greenlee1, J B Burns, J W Rose, K A Jaeckle, S Clawson.   

Abstract

Paraneoplastic cerebellar degeneration accompanying gynecological or breast malignancies is frequently associated with an autoantibody response, termed "type I" or "anti-Yo" directed against cytoplasmic antigens of cerebellar Purkinje cells. The role of this antibody response in the pathogenesis of paraneoplastic cerebellar degeneration is unknown; however, it is also not known whether anti-Purkinje cell antibodies from the systemic circulation bind to target Purkinje cell antigens under the conditions of brain inflammation and blood-brain barrier disruption, which are frequently present at the onset of cerebellar symptoms. Inbred Lewis rats received intraperitoneal injections of type I or normal IgG in the setting of blood-brain barrier disruption induced by adoptive transfer of experimental allergic encephalomyelitis (EAE) and were killed after 24, 48, and 96 h. Brains of these animals were studied histologically for evidence of EAE and immunohistochemically for binding of human or endogenous rat IgG to target neurons. Rat IgG was detected around vessels and in Purkinje cells of all animals studied. Human IgG was detected around vessels of all animals. In animals examined 96h after receiving type I human IgG, human IgG was identified within processes of Purkinje cells and within occasional Purkinje cell bodies. Uptake of type I IgG by other cell types was not observed, and neuronal uptake of IgG was not seen in brains of animals receiving normal human IgG. Our data demonstrate that circulating type I IgG is internalized by cerebellar Purkinje cells in the setting of blood-brain barrier disruption and suggest a mechanism by which an antibody response directed against cytoplasmic antigens of Purkinje cells may reach target antigens at the onset of paraneoplastic cerebellar degeneration.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7610765     DOI: 10.1007/BF00309627

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  22 in total

1.  Selective extraction of small and large molecules from the cerebrospinal fluid by Purkinje neurons.

Authors:  L F Borges; P J Elliott; R Gill; S D Iversen; L L Iversen
Journal:  Science       Date:  1985-04-19       Impact factor: 47.728

2.  Immunoperoxidase labelling of rat brain sections with sera from patients with paraneoplastic cerebellar degeneration and systemic neoplasia.

Authors:  J E Greenlee; H R Brashear; R M Herndon
Journal:  J Neuropathol Exp Neurol       Date:  1988-09       Impact factor: 3.685

3.  Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes.

Authors:  H F Furneaux; L Reich; J B Posner
Journal:  Neurology       Date:  1990-07       Impact factor: 9.910

4.  Autoimmune paraneoplastic cerebellar degeneration: ultrastructural localization of antibody-binding sites in Purkinje cells.

Authors:  M Rodriguez; L I Truh; B P O'Neill; V A Lennon
Journal:  Neurology       Date:  1988-09       Impact factor: 9.910

5.  Anticerebellar antibodies in serum and cerebrospinal fluid of a patient with oat cell carcinoma of the lung and paraneoplastic cerebellar degeneration.

Authors:  J E Greenlee; H L Lipton
Journal:  Ann Neurol       Date:  1986-01       Impact factor: 10.422

6.  Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen.

Authors:  K A Jaeckle; F Graus; A Houghton; C Cardon-Cardo; S L Nielsen; J B Posner
Journal:  Ann Neurol       Date:  1985-11       Impact factor: 10.422

7.  Effect of intraventricular injection of an anti-Purkinje cell antibody (anti-Yo) in a guinea pig model.

Authors:  F Graus; I Illa; M Agusti; T Ribalta; F Cruz-Sanchez; C Juarez
Journal:  J Neurol Sci       Date:  1991-11       Impact factor: 3.181

8.  Intraneuronal accumulation of myeloma proteins.

Authors:  L F Borges; N A Busis
Journal:  Arch Neurol       Date:  1985-07

9.  Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein.

Authors:  C Linington; M Bradl; H Lassmann; C Brunner; K Vass
Journal:  Am J Pathol       Date:  1988-03       Impact factor: 4.307

10.  Anticerebellar antibodies in neurologically normal patients with ovarian neoplasms.

Authors:  H R Brashear; J E Greenlee; K A Jaeckle; J W Rose
Journal:  Neurology       Date:  1989-12       Impact factor: 9.910

View more
  18 in total

1.  Abnormal Purkinje cell activity in vivo in experimental allergic encephalomyelitis.

Authors:  Carl Y Saab; Matthew J Craner; Yuko Kataoka; Stephen G Waxman
Journal:  Exp Brain Res       Date:  2004-04-29       Impact factor: 1.972

2.  Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures.

Authors:  John E Greenlee; Susan A Clawson; Kenneth E Hill; Blair L Wood; Ikuo Tsunoda; Noel G Carlson
Journal:  J Neuropathol Exp Neurol       Date:  2010-10       Impact factor: 3.685

Review 3.  Neuronal autoantigens--pathogenesis, associated disorders and antibody testing.

Authors:  Eric Lancaster; Josep Dalmau
Journal:  Nat Rev Neurol       Date:  2012-06-19       Impact factor: 42.937

4.  Autoantibodies directed against glutamate decarboxylase interfere with glucose-stimulated insulin secretion in dispersed rat islets.

Authors:  Varun Kamat; Jared R Radtke; Qingxun Hu; Wang Wang; Ian R Sweet; Christiane S Hampe
Journal:  Int J Exp Pathol       Date:  2022-03-04       Impact factor: 2.793

Review 5.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

6.  Cerebellar Purkinje cells incorporate immunoglobulins and immunotoxins in vitro: implications for human neurological disease and immunotherapeutics.

Authors:  Kenneth E Hill; Susan A Clawson; John W Rose; Noel G Carlson; John E Greenlee
Journal:  J Neuroinflammation       Date:  2009-10-29       Impact factor: 8.322

Review 7.  'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2: Anti-PKC-gamma, anti-GluR-delta2, anti-Ca/ARHGAP26 and anti-VGCC.

Authors:  S Jarius; B Wildemann
Journal:  J Neuroinflammation       Date:  2015-09-17       Impact factor: 8.322

Review 8.  'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook.

Authors:  S Jarius; B Wildemann
Journal:  J Neuroinflammation       Date:  2015-09-17       Impact factor: 8.322

Review 9.  Active immunotherapy options for Alzheimer's disease.

Authors:  Bengt Winblad; Ana Graf; Marie-Emmanuelle Riviere; Niels Andreasen; J Michael Ryan
Journal:  Alzheimers Res Ther       Date:  2014-01-30       Impact factor: 6.982

Review 10.  Paraneoplastic neurological syndrome: an evolving story.

Authors:  Jiraporn Jitprapaikulsan; Pritikanta Paul; Smathorn Thakolwiboon; Shivam Om Mittal; Sean J Pittock; Divyanshu Dubey
Journal:  Neurooncol Pract       Date:  2021-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.